51-00-3

Usage

InChI:InChI=1/C11H11NO5/c1-6(13)12-8-3-4-9(11(15)16)10(5-8)17-7(2)14/h3-5H,1-2H3,(H,12,13)(H,15,16)

Upstream product

• 108-24-7 acetic anhydride 
• 50-86-2 4-acetamidosalicylic acid 
• 75-36-5 acetyl chloride 
• 65-49-6 4-Aminosalicylic acid 
• 17336-10-6 2-acetoxy-4-nitrobenzoic acid 
• 16426-64-5 2-bromo-4-nitrobenzoic acid 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 

Downstream Products

• 122217-95-2 bis-[4-(2-acetoxy-4-acetylamino-benzoyloxy)-phenyl]-sulfone 
• 6625-92-9 4-acetylamino-5-bromo-2-hydroxy-benzoic acid 
• 38059-73-3 5-acetylamino-2-methoxycarbonyl-1-acetoxybenzene 
• 37987-05-6 2-acetoxy-4-acetylamino-benzoyl chloride 
• 99185-78-1 4-amino-2-hydroxy-benzoic acid thiazol-2-ylamide 
• 99072-94-3 4-amino-2-hydroxy-benzoic acid-(5-methyl-[1,3,4]thiadiazol-2-ylamide) 
• 78154-65-1 4-amino-2-hydroxy-benzoic acid anilide 
• 858478-67-8 2-acetoxy-4-acetylamino-benzoic acid thiazol-2-ylamide 
• 109016-83-3 4-amino-2-hydroxy-benzoic acid-(4-sulfamoyl-anilide) 
• 6625-93-0 4-amino-5-bromo-2-hydroxy-benzoic acid 
• 279215-23-5 4-acetylamino-2,N-dihydroxy-N-isopropyl-benzamide 
• 693257-35-1 4-acetylamino-N-(3-benzyloxy-phenyl)-2-hydroxy-benzamide 

Relevant academic research and scientific papers

The first general synthesis of N-substituted 1,2-benzisoxazolin-3-ones

A convenient synthesis of the title compounds has been developed. Key synthetic steps include: (1) conversion of the readily available salicylic acid derivatives to the corresponding N-substituted salicylhydroxamic acids; (2) cyclization of the hydroxamic acids under Mitsunobu conditions to give the title compounds. (C) 2000 Elsevier Science Ltd.

Medicaments for the selective treatment of tumor tissues

Medicinal products for the selective control of tumor tissue and a method for control of such tumor tissue by administration of such product to a host. The products comprise: (a) two different compounds having a pH below 7 when the compounds are present i

Benzoic acid derivatives and use thereof

A pharmaceutical composition for use in the treatment of psoriasis comprises 4-aminosalicylic acid (4-ASA) or 5-aminosalicylic acid (5-ASA) or a functional derivative thereof, said pharmaceutical composition being in a form suitable for topical administration. Furthermore, 4- or 5-ASA or a functional derivative thereof are used for the manufacture of pharmaceutical compositions for treating psoriasis, atopic dermatitis, allergic dermatitis, contact dermatitis, seborrhoic dermatitis, or acne diseases. The derivatives have the formulae: STR1 where W is COOX, wherein X is H, Li, Na, K, Mg0.5, Ca0.5, Zn0.5, Al0.33, Fe(II)0.5, Fe(III)0.33, NH4, NH3 R1, NH2 R12, NHR13, NR14, or R1, where R1 is substituted or unsubstituted C1-6 -alkyl, aryl-C1-4 -alkyl, or heteroaryl-C1-4 -alkyl; or COX, where X is NR1 R1', where R1' has the same meaning as R1 defined above and R1 and R1' may be identical or different; Y is H or R1 CO, where R1 is defined as above; Z1 and Z2, which may be identical or non-identical are H, R1 or R1 CO, where R1 is defined as above, or Z1 and Z2 represent R2, where R2 is substituted or unsubstituted C1-6 -alkylidene or aryl-C1-6 -alkylidene, or heteroaryl-C1-6 -alkylidene, or Z1, Z2 together with the nitrogen atom to which they are attached may represent a 3 to 7 membered saturated or unsaturated heterocyclic ring, or may represent a group of the formula --N=N--R3 where R3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.